2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a rare type of cancer affecting the blood and bone marrow, characterized by abnormal B lymphocytes with fine hair-like projections. While it accounts for only about 2% of all leukemias, its distinct cellular features present unique challenges in treatment. Recent research in cancer therapy has shown promising advancements in managing HCL. Targeted therapies, such as monoclonal antibodies and immunotoxins, have improved outcomes by specifically targeting the abnormal cells while sparing healthy ones. Additionally, advancements in understanding the molecular mechanisms underlying HCL have led to the development of novel targeted agents, offering hope for more effective and less toxic treatments. As researchers delve deeper into the molecular intricacies of HCL, personalized therapies tailored to individual patients' genetic profiles are on the horizon, promising even greater strides in combating this rare form of leukemia.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China